Publicaciones en colaboración con investigadores/as de Complejo Asistencial de Ávila (17)

2023

  1. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

    Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437

  2. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain

    European Journal of Haematology, Vol. 111, Núm. 3, pp. 485-490

2022

  1. Uroflujometría en el adulto

    FMC: Formación Médica Continuada en Atención Primaria, Vol. 29, Núm. 7, pp. 371-374

2021

  1. Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with pre-existing primary immune thrombocytopenia (ITP) in Spain

    British Journal of Haematology, Vol. 194, Núm. 3, pp. 537-541

  2. Traumatismos genitourinarios y del aparato urinario inferior y del aparato genital masculino

    Nefrología y urología (Ediciones Universidad de Salamanca), pp. 361-369

  3. Traumatismos genitourinarios y del aparato urinario superior

    Nefrología y urología (Ediciones Universidad de Salamanca), pp. 351-360

2020

  1. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

    American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509

  2. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

    Experimental Hematology and Oncology

  3. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

    Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1885-1893

2019

  1. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

    Blood

2017

  1. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice

    International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516

  2. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970

2016

  1. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

    European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302

  2. Síndrome de Turner: análisis de 42 casos

    Medicina Clinica, Vol. 147, Núm. 8, pp. 348-351

2015

  1. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

2014

  1. COL4A4 gene study of a european population: Description of new mutations causing autosomal dominant alport syndrome

    International Journal of Molecular Epidemiology and Genetics, Vol. 5, Núm. 4, pp. 177-184

  2. Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain

    BMC Ophthalmology, Vol. 14, Núm. 1